{
    "clinical_study": {
        "@rank": "159753", 
        "arm_group": {
            "arm_group_label": "Treatment (gemcitabine hydrochloride)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial studies the side effects and best dose of gemcitabine hydrochloride in\n      treating patients with locally advanced pancreatic cancer. Drugs used in chemotherapy, such\n      as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells,\n      either by killing the cells or by stopping them from dividing."
        }, 
        "brief_title": "Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer", 
        "condition": [
            "Duct Cell Adenocarcinoma of the Pancreas", 
            "Stage III Pancreatic Cancer", 
            "Stage IV Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerate dose (MTD) of intra-tumoral injection of gemcitabine\n      (gemcitabine hydrochloride) when administered as a one time initial induction therapy in\n      conjunction (=< 33 hours) prior to conventional multimodality treatment for locally advanced\n      pancreatic cancer (LAPC).\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the initial and delayed toxicity associated with this treatment regimen.\n\n      OUTLINE: This is a dose-escalation study.\n\n      Patients receive gemcitabine hydrochloride intratumorally (IT) on day 1. Within 33 hours,\n      patients receive standard chemotherapy comprising fluorouracil intravenously (IV) on days 1,\n      8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.\n\n      After completion of study treatment, patients are followed up for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytology proven pancreatic ductal carcinoma\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0,1 or 2\n\n          -  Absolute neutrophil count (ANC) >= 1500\n\n          -  Platelets (PLT) >= 100,000\n\n          -  Hemoglobin (HgB) > 9.0 g/dL\n\n          -  Total bilirubin < 2.0 x upper limit of normal (ULN)\n\n          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =<\n             5 x ULN\n\n          -  Creatinine =< 1.5 mg/dL\n\n          -  Negative pregnancy test done =< 14 days prior to registration, for women of\n             childbearing potential only\n\n          -  Provide informed written consent\n\n          -  Imaging, a combination of at least two of the following (computed tomography [CT],\n             magnetic resonance imaging [MRI], endoscopic ultrasound [EUS]) staging the pancreatic\n             mass as \"locally advanced\"\n\n          -  EUS clinically indicated for staging, and/or celiac neurolysis\n\n          -  Resection declined by surgical staff based on designation of LAPC\n\n          -  Willing to provide blood samples\n\n          -  Willing to receive their standard multimodality therapy at Mayo Clinic, Rochester\n\n          -  Willing to return to Mayo Clinic, Rochester during the observation phase\n\n        Exclusion Criteria:\n\n          -  Any of the following because this study involves an agent that has known genotoxic,\n             mutagenic and teratogenic effects:\n\n               -  Pregnant women\n\n               -  Nursing women\n\n               -  Men or women of childbearing potential who are unwilling to employ adequate\n                  contraception\n\n          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the\n             judgment of the investigator, would make the patient inappropriate for entry into\n             this study or interfere significantly with the proper assessment of safety and\n             toxicity of the prescribed regimens\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Receiving any other investigational agent which would be considered as a treatment\n             for the primary neoplasm\n\n          -  Any prior treatment (chemotherapy, radiation) for pancreatic cancer\n\n          -  Other active malignancy =< 3 years prior to registration; EXCEPTIONS: Non-melanotic\n             skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior\n             malignancy, they must not be receiving other specific treatment for their cancer\n\n          -  History of myocardial infarction =< 168 days (6 months), or congestive heart failure\n             requiring use of ongoing maintenance therapy for life-threatening ventricular\n             arrhythmias\n\n          -  Prior pancreatic surgery\n\n          -  Pancreatic tumor histology other than carcinoma (e.g. islet cell, lymphoma, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893294", 
            "org_study_id": "MC1241", 
            "secondary_id": "NCI-2013-00798"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (gemcitabine hydrochloride)", 
                "description": "Given IT", 
                "intervention_name": "gemcitabine hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "dFdC", 
                    "difluorodeoxycytidine hydrochloride", 
                    "gemcitabine", 
                    "Gemzar"
                ]
            }, 
            {
                "arm_group_label": "Treatment (gemcitabine hydrochloride)", 
                "description": "Given IV", 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "5-fluorouracil", 
                    "5-Fluracil", 
                    "5-FU"
                ]
            }, 
            {
                "arm_group_label": "Treatment (gemcitabine hydrochloride)", 
                "description": "Undergo radiation therapy", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "irradiation", 
                    "radiotherapy", 
                    "therapy, radiation"
                ]
            }, 
            {
                "arm_group_label": "Treatment (gemcitabine hydrochloride)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Gemcitabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 7, 2014", 
        "location": {
            "contact": {
                "last_name": "Mayo Clinic Clinical Trials Referral Office", 
                "phone": "507-538-7623"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Michael J. Levy, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial of Intra-Tumoral Gemcitabine Therapy for Locally Advanced Pancreatic Carcinoma", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Michael Levy, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MTD of gemcitabine hydrochloride defined as the dose at which no more than 3 of 6 patients experience grade 3 or greater adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0", 
            "safety_issue": "Yes", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893294"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Michael Levy, M.D.", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.", 
                "measure": "Incidence of immediate adverse events associated with this treatment, graded according to the NCI CTCAE v3.0", 
                "safety_issue": "Yes", 
                "time_frame": "Within 72 hours of EUS"
            }, 
            {
                "description": "The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.", 
                "measure": "Incidence of delayed adverse events associated with this treatment, graded according to the NCI CTCAE v3.0", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks after completing standard systemic chemotherapy"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}